Seer Introduces First-of-its-kind Proteogenomics Workflow to Link Genetic Modifications with Protein Variants with Proteograph ™ Analysis Suite 2.0
REDWOOD CITY, Calif., Aug. 03, 2022 (WORLD NEWSWIRE)– Seer Inc. (NASDAQ: SEER), a life sciences company advertising a disruptive brand-new platform for proteomics, today revealed a new Proteogenomics Workflow that integrates deep, impartial proteomics with genomics, powered by the Proteograph Analysis Suite 2.0, Seer’s software suite for data analysis and results visualization. The release of the workflow marks another milestone on Seer’s journey to enabling accurate, high-resolution, peptide-level proteogenomics at scale and follows the development of its Proteogenomics Consortium in the very first half of this year.
Each protein variant provides increase to a various profile of peptides, which the Proteograph Item Suite can identify and quantify, dealing with unique and known protein variations at the peptide level. Present affinity-based methods study modifications for a set of predefined protein targets, missing possibly essential variants of these predefined proteins and providing an insufficient view of the relationship between the genome and the proteome.
Seer’s Proteograph Analysis Suite 2.0 is a key part of the Proteograph ™ Item Suite, which supplies unbiased, deep, fast proteomics at scale that is peptide-centric, and makes it possible for high-resolution recognition of protein variations. This next version of the Proteograph Analysis Suite includes a Proteogenomic Workflow that maps proteomic, peptide-level data to genomic information to determine sample-specific variation peptides not captured in canonical reference databases. The workflow summarizes lead to interactive tables and plots, makes it possible for the visualization of recognized peptides’ relationship to gene structure, protein domain info, and functional areas; and produces browsable peptide data maps at the amino acid level. The Proteograph Analysis Suite’s intuitive visualizations make it faster and much easier to find protein targets for a broad range of applications.
” We’re enjoyed provide PAS 2.0, this brand-new Proteogenomic Workflow, and our other exciting future enhancements that make it much easier for various client groups to adopt deep, unbiased proteogenomics at scale,” said Serafim Batzoglou, Ph.D., Elder Vice President, Data at Seer. “Making proteomic analysis tools more accessible for researchers is among Seer’s main concerns, and today’s announcement is another step towards accomplishing that goal.”
The launch of the Proteogenomic Workflow advances Seer’s commitment to allowing more comprehensive access to proteogenomic tools. In January, Seer formed the Proteogenomics Consortium with Discovery Life Sciences, a global leader in biomarker advancement and biospecimen options utilizing proteomic, genomic, cell, and immunohistochemistry innovations, and SCIEX, a worldwide leader in life science analytical technologies. The cooperation is planned to allow genomics consumers to add deep, objective proteomics information more quickly to their studies, allowing the discovery of new protein variations and novel biomarkers that might lead to restorative breakthroughs.
” At Discovery Life Sciences, we are delighted by the features we’ve seen shown by this brand-new tool and aspire to integrate the new features in the Proteograph Analysis Suite 2.0 into our services pipeline at our brand-new center outside Boston,” stated Michael Pisano, Ph.D., Executive Vice President, Proteomics at Discovery Life Sciences.
The Proteograph Analysis Suite v2.0 rollout is underway, with Seer consumers having immediate access to the new workflow and functions in the software application.
Seer’s Proteograph ™ Product Suite is an integrated service that consists of exclusive crafted nanoparticles, consumables, automation instrumentation and software application to carry out deep, unbiased proteomic analysis at scale in a matter of hours. Seer’s Proteograph Product Suite is for research usage only and is not planned for diagnostic procedures.
Forward-looking statements may include known and unknown threats, uncertainties and other aspects that may trigger Seer’s actual results, performance, or achievements to be materially different from those revealed or indicated by the positive statements. These statements include but are not restricted to declarations concerning Seer’s Proteograph Analysis Suite’s functionality and capability to make it possible for accurate, high-resolution, peptide-level proteogenomics at scale and Seer’s partnership with Discovery Life Sciences and SCIEX. These and other dangers are described more completely in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time.
Seer’s Proteograph Analysis Suite 2.0 is a key component of the Proteograph ™ Item Suite, which provides unbiased, deep, rapid proteomics at scale that is peptide-centric, and enables high-resolution recognition of protein versions. Seer’s Proteograph ™ Product Suite is an integrated option that consists of proprietary crafted nanoparticles, consumables, automation instrumentation and software to carry out deep, impartial proteomic analysis at scale in a matter of hours. Seer’s Proteograph Product Suite is for research use just and is not intended for diagnostic treatments. These declarations include however are not limited to declarations regarding Seer’s Proteograph Analysis Suite’s functionality and ability to make it possible for accurate, high-resolution, peptide-level proteogenomics at scale and Seer’s partnership with Discovery Life Sciences and SCIEX. These and other dangers are described more totally in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time.